A groundbreaking clinical investigation has revealed that administering immunotherapy prior to surgical intervention significantly elevates the prospects for individuals battling specific forms of colorectal cancer. The NEOPRISM-CRC study, a pioneering effort, demonstrated that a concentrated, nine-week regimen of immunotherapy, when delivered before surgery, has resulted in patients remaining entirely free of detectable cancer for a period approaching three years. This innovative approach bypasses the conventional post-operative chemotherapy sequence for a subset of patients, yielding unexpectedly robust and sustained remission rates.
The research, spearheaded by a collaborative team from University College London (UCL) and University College London Hospitals (UCLH), focused on patients diagnosed with stage two or three colorectal cancer. The findings indicate that the early introduction of pembrolizumab, a type of immunotherapy, not only eradicated visible tumors in a substantial portion of participants but also prevented the return of microscopic cancer cells that might have otherwise persisted. This pre-operative strategy appears to prime the immune system to more effectively combat residual disease, a crucial factor in preventing long-term recurrence.
Initial analyses of the NEOPRISM-CRC trial indicated that an impressive 59% of participants exhibited no discernible traces of cancer following the completion of their immunotherapy course and subsequent surgery. Crucially, as the study has progressed to a 33-month follow-up mark, not a single patient in this cohort has experienced a relapse. This remarkable outcome encompasses individuals whose tumors were entirely eliminated by the immunotherapy and those who still harbored microscopic remnants of the malignancy post-treatment. In every instance, these residual cancer cells failed to proliferate or metastasize over the extended observation period.
This prolonged cancer-free status presents a striking contrast to the typical trajectory observed with standard treatment protocols. In conventional care pathways, where surgery is often followed by several months of chemotherapy, approximately 25% of patients are expected to experience a recurrence of their cancer within a three-year timeframe. The outcomes from the NEOPRISM-CRC study strongly suggest that initiating treatment with immunotherapy may confer a more enduring protective shield against cancer progression and relapse.
Beyond the encouraging remission rates, the research delved into the underlying mechanisms driving the immunotherapy’s success and explored methods for identifying patients most likely to benefit from this tailored approach. A key development was the creation of personalized diagnostic tools, utilizing blood samples, capable of detecting the presence of circulating tumor DNA (ctDNA). The presence or absence of ctDNA in the bloodstream emerged as a significant predictor of treatment efficacy.
These advanced blood tests hold the potential to offer clinicians an early and reliable indicator of whether the immunotherapy has successfully eradicated the cancer. This capability could revolutionize treatment monitoring, allowing for timely adjustments to therapeutic strategies based on individual patient responses. The ability to ascertain treatment success through a non-invasive blood test could streamline clinical decision-making and improve patient management.
Dr. Kai-Keen Shiu, the Chief Investigator for the NEOPRISM-CRC trial and a Consultant Medical Oncologist at UCLH, expressed profound optimism regarding the study’s results. "Observing that no patients have experienced a recurrence of cancer after nearly three years of follow-up is exceptionally encouraging," Dr. Shiu stated. "This strengthens our conviction that pembrolizumab represents a safe and highly effective therapeutic option for enhancing outcomes in patients with high-risk bowel cancers." He further elaborated on the exciting prospect of predicting patient response through personalized blood tests and immune profiling. "These tools could empower us to customize our treatment strategies, distinguishing between patients who are responding exceptionally well and might require less intensive therapy, and those at higher risk of disease progression or relapse who would benefit from additional interventions," he added.
Understanding the broader landscape of colorectal cancer is essential to appreciating the significance of these findings. Bowel cancer, encompassing both colon and rectal cancers, ranks as the fourth most prevalent malignancy in the United Kingdom, with an estimated 44,000 new cases diagnosed annually. While historically more common in older demographics, there has been a concerning upward trend in diagnoses among individuals under the age of 50. The prognosis for colorectal cancer is intrinsically linked to the stage at which it is detected. Early-stage cancers (stage one) boast a five-year survival rate of approximately 90%, whereas survival rates decline considerably for later stages, dropping to 65% at stage three and a mere 10% at stage four. Certain tumor subtypes also exhibit a greater propensity to resist conventional treatments and recur.
The NEOPRISM-CRC trial specifically enrolled 32 patients diagnosed with stage two or three colorectal cancer possessing a particular genetic characteristic known as mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-high). This specific tumor subtype, which responds favorably to immunotherapy, accounts for roughly 10-15% of all colorectal cancer cases, translating to an estimated 2,000 to 3,000 patients annually in the UK. The trial’s design involved administering up to nine weeks of pembrolizumab prior to surgery, deviating from the conventional sequence of surgery followed by an extended course of chemotherapy. Participants were then subjected to rigorous monitoring over an extended period. The latest findings from this pivotal study were formally presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego in 2026. The research benefited from the participation of multiple hospitals across the UK, with UCL and UCLH spearheading the initiative, and the biotech company Personalis contributing crucial expertise to the data analysis.
Further scientific inquiry within the study yielded novel insights into the precise mechanisms by which immunotherapy elicits these lasting therapeutic effects. Professor Marnix Jansen of the UCL Cancer Institute and UCLH remarked, "These results not only validate the enduring nature of the responses we observed nearly three years ago but also furnish critical biological understanding into why immunotherapy is so effective in this specific clinical context." The research team’s investigations revealed a strong correlation between the disappearance of tumor DNA from the bloodstream and a significantly higher likelihood of long-term cancer freedom.
Yanrong Jiang, the study’s lead author, articulated the team’s excitement regarding the ability to meticulously track patient progress using the personalized blood tests. "When tumor DNA vanished from the bloodstream, patients demonstrated a substantially greater probability of achieving complete remission, a finding that aligns with the long-term outcomes we are now witnessing," Jiang stated. "Furthermore, we observed that immune profiling conducted on tumor tissue, before patients commenced their initial treatment cycle, can serve as a valuable predictor of response. Our hope is that these diagnostic tools can be integrated into clinical practice to guide treatment decisions in a more pragmatic and timely manner."
The profound impact of this innovative treatment approach is vividly illustrated by the personal journey of Christopher Burston, a 73-year-old gentleman from Portland, Dorset. Mr. Burston was diagnosed with colorectal cancer in February 2023, following a routine screening that detected blood in his stool. Subsequent investigations, including a colonoscopy, confirmed the presence of a cancerous growth in his bowel. Shortly after his diagnosis, he was presented with the opportunity to participate in the NEOPRISM-CRC trial and opted to enroll, traveling to London for his treatment.
He underwent three doses of immunotherapy over a nine-week period before proceeding to surgery in May 2023. Mr. Burston reported a smooth recovery with minimal side effects. Reflecting on the outcome of his surgery, he recounted his doctor’s observation that the cancer had "melted away," underscoring the remarkable efficacy of the immunotherapy. He recalled the visual evidence from his initial colonoscopy, which revealed a substantial tumor, emphasizing the seriousness of his stage three diagnosis.
Nearly three years post-treatment, Mr. Burston remains entirely cancer-free and has successfully resumed his normal daily activities. "The recovery went smoothly; I experienced no complications," he shared. "Since then, I’ve felt pretty much back to my usual self. I feel incredibly fortunate to have reached a point where my primary concern is my age, rather than cancer or any other illness." His experience serves as a powerful testament to the transformative potential of pre-operative immunotherapy in revolutionizing outcomes for advanced colorectal cancer patients.
About the Author
